- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Seen in the ED: Hematochezia in a 1-year-old Girl
Intermittent pain causing the child to cry and an episode of bright red rectal bleeding are described by the mother. Review labs and imaging: What's your diagnosis?
Patient history. An almost 1-year-old girl is brought to the emergency department for intermittent pain causing her to cry, followed by an episode of bright red rectal bleeding. She vomited once but her mother denies any fever or other complaints. They recently returned from a trip to Mexico, but no one else is ill. Mother noticed her right nipple has a crack but didn’t see any bleeding coming from it.
Vital signs and physical examination. Vital signs are normal. Physical exam is normal except for the child seeming tired. Mom says it’s probably because she missed her nap yesterday and was awake a good portion of the night due to the pain
Relevant test results
Labs: CBC, coagulation profile, basic metabolic panel all are normal
Imaging
What is the most likely diagnosis?
FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment
October 14th 2025FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.
Clinical Tips for Using Antibiotics and Corticosteroids in IBD
January 5th 2013The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
September 30th 2025The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.
